Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
FC(PO)+R
- Cancer Type
- Hematologic, Leukemia - Chronic Lymphocytic (CLL)
- Intent
-
Palliative
- Regimen Category
-
Evidence-informed
- Funding Program
-
New Drug Funding Program Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia ODB - General Benefit cyclophosphamide - oral tablets
- Drugs Used
- riTUXimab , fludarabine , cyclophosphamide , riTUXimab (subcut)
Regimen Monograph
Aug 2020
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 27, 2026
